Novavax Inc Cash Flow Conversion Efficiency
Novavax Inc cash flow conversion efficiency. Based on the latest financial reports, Novavax Inc (NVAX) has a cash flow conversion efficiency ratio of 0.395x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-75.41 Million) by net assets ($-190.71 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Novavax Inc (1996–2025)
Cash flow conversion efficiency of Novavax Inc from 1996 to 2025. This chart illustrates how Novavax Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Novavax Inc share price for real-time trading data and today's change.
Novavax Inc Cash Flow Conversion Ratio Explained
Novavax Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Novavax Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Novavax Inc ranked by their cash flow conversion efficiency. Also see Novavax Inc market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AeroSpace Technology of Korea
KQ:067390
|
0.020x |
|
Gansu Guofang Gongmao(Grp)
SHG:601086
|
0.031x |
|
Ganzhou Tengyuan Cobalt New Material Co. Ltd.
SHE:301219
|
N/A |
|
Zhejiang Huatie Constr Safety
SHG:603300
|
0.167x |
|
Grupo Nacional Provincial S.A.B
MX:GNP
|
0.029x |
|
Grupo Aeroméxico S.A.B. de C.V
MX:AEROMEX
|
-0.311x |
|
Couchbase Inc
NASDAQ:BASE
|
-0.028x |
|
Xiamen Meiya Pico Information
SHE:300188
|
-0.013x |
Annual Cash Flow Conversion Efficiency for Novavax Inc (1996–2025)
The table below shows the annual cash flow conversion efficiency of Novavax Inc from 1996 to 2025. Review free cash flow generation of Novavax Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-127.75 Million | $-244.63 Million | 1.915x | +1268.96% |
| 2024-12-31 | $-623.84 Million | $-87.26 Million | 0.140x | -85.95% |
| 2023-12-31 | $-716.93 Million | $-713.97 Million | 0.996x | +51.82% |
| 2022-12-31 | $-634.08 Million | $-415.94 Million | 0.656x | +171.43% |
| 2021-12-31 | $-351.67 Million | $322.95 Million | -0.918x | -1253.93% |
| 2020-12-31 | $627.21 Million | $-42.54 Million | -0.068x | -109.23% |
| 2019-12-31 | $-186.02 Million | $-136.62 Million | 0.734x | -33.27% |
| 2018-12-31 | $-167.94 Million | $-184.82 Million | 1.101x | -19.27% |
| 2017-12-31 | $-101.73 Million | $-138.70 Million | 1.363x | -97.04% |
| 2016-12-31 | $-5.55 Million | $-255.47 Million | 46.063x | +10791.80% |
| 2015-12-31 | $292.67 Million | $-126.09 Million | -0.431x | -47.62% |
| 2014-12-31 | $229.62 Million | $-67.01 Million | -0.292x | -30.77% |
| 2013-12-31 | $203.23 Million | $-45.36 Million | -0.223x | +1.76% |
| 2012-12-31 | $80.24 Million | $-18.23 Million | -0.227x | +48.23% |
| 2011-12-31 | $53.85 Million | $-23.63 Million | -0.439x | +21.13% |
| 2010-12-31 | $59.05 Million | $-32.85 Million | -0.556x | -26.19% |
| 2009-12-31 | $74.47 Million | $-32.83 Million | -0.441x | +17.50% |
| 2008-12-31 | $45.49 Million | $-24.31 Million | -0.534x | -26.03% |
| 2007-12-31 | $63.06 Million | $-26.74 Million | -0.424x | -169.14% |
| 2006-12-31 | $94.00 Million | $-14.81 Million | -0.158x | -34.67% |
| 2005-12-31 | $49.65 Million | $-5.81 Million | -0.117x | +87.06% |
| 2004-12-31 | $33.28 Million | $-30.10 Million | -0.904x | -85.26% |
| 2003-12-31 | $35.94 Million | $-17.55 Million | -0.488x | +81.29% |
| 2002-12-31 | $8.07 Million | $-21.07 Million | -2.609x | -1471.21% |
| 2001-12-31 | $27.49 Million | $-4.57 Million | -0.166x | +47.38% |
| 2000-12-31 | $31.82 Million | $-10.04 Million | -0.316x | +76.12% |
| 1999-12-31 | $2.80 Million | $-3.70 Million | -1.321x | -10.12% |
| 1998-12-31 | $3.00 Million | $-3.60 Million | -1.200x | -85.71% |
| 1997-12-31 | $6.50 Million | $-4.20 Million | -0.646x | +0.14% |
| 1996-12-31 | $5.10 Million | $-3.30 Million | -0.647x | -- |
About Novavax Inc
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Com… Read more